Bill

HR 1476

PLASMA Act

119th Congress Introduced by Don Davis and 5 co-sponsors

The PLASMA Act ensures patients have reliable access to life-saving plasma-derived medicines by streamlining regulations and strengthening supply chains.

Introduced in House

WeVote Research Nonpartisan

Bill Summary · HR 1476

Summary of HR 1476 - PLASMA Act

Overview

The Preserving Life-saving Access to Specialty Medicines in America Act, commonly referred to as the PLASMA Act, was introduced in the House of Representatives on February 21, 2025. The bill aims to enhance access to specialty medicines, particularly those derived from human plasma, which are critical for treating various medical conditions.

Purpose and Intent

The primary purpose of the PLASMA Act is to ensure that patients have uninterrupted access to life-saving specialty medicines. These medicines are often essential for individuals with chronic illnesses, rare diseases, or conditions requiring specific therapies derived from human plasma. The bill seeks to address potential barriers in the supply chain and regulatory processes that may hinder access to these vital treatments.

Key Provisions

While the full text of the bill has not been detailed in the provided information, the following key provisions can be anticipated based on the bill's title and intent:

Regulatory Streamlining: The bill may propose measures to simplify the regulatory framework governing the production and distribution of plasma-derived medicines.
Supply Chain Support: It is likely to include provisions aimed at strengthening the supply chain for plasma collection and processing to ensure a steady availability of these medicines.
Patient Access Initiatives: The PLASMA Act may introduce initiatives to enhance patient education and outreach regarding the availability and use of specialty medicines.

Affected Parties

The PLASMA Act would primarily impact:

Patients: Individuals requiring specialty medicines derived from human plasma would benefit from improved access and availability.
Healthcare Providers: Physicians and healthcare professionals who prescribe these treatments would see changes in the availability of medications for their patients.
Pharmaceutical Companies: Companies involved in the production and distribution of plasma-derived medicines may need to adapt to new regulatory requirements and processes.

Legislative Process

Introduced: February 21, 2025
Referred to Committees: The bill has been referred to the Committee on Energy and Commerce and the Committee on Ways and Means for consideration. The timeline for further action will be determined by the Speaker of the House.

Related Legislation

The PLASMA Act has a companion bill, S 694, which is being considered in the Senate, indicating a bipartisan interest in addressing the issues surrounding access to specialty medicines.

This summary provides an overview of the PLASMA Act, highlighting its purpose, key provisions, and potential impact on patients and healthcare providers. Further details will emerge as the legislative process unfolds.

Compiled from official sources — confirm details with the bill’s official record.